Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
Mithramycin inhibits transcription by binding to G/C-rich sequences, thereby preventing regulatory protein binding. However, it is also possible that mithramycin inhibits gene expression by preventing intramolecular triplex DNA assembly. We tested this hypothesis using the DNA triplex adopted by the murine c-myb proto-oncogene. The 5'-regulatory region of c-myb contains two polypurine:polypyrimidine tracts with imperfect mirror symmetry, which are highly conserved in the murine and human c-myb sequences. The DNA binding drugs mithramycin and distamycin bind to one of these regions as determined by DNase I protection assay. Gel mobility shift assays, nuclease and chemical hypersensitivity and 2D-gel topological analyses as well as triplex-specific antibody binding studies confirmed the formation of purine*purine:pyrimidine inter- and pyrimidine*purine:pyrimidine intra-molecular triplex structures in this sequence. Mithramycin binding within the triplex target site displaces the major groove-bound oligonucleotide, and also abrogates the supercoil-dependent H-DNA formation, whereas distamycin binding had no such effects. Molecular modeling studies further support these observations. Triplex-specific antibody staining of cells pretreated with mithramycin demonstrates a reversal of chromosomal triplex structures compared to the non-treated and distamycin-treated cells. These observations suggest that DNA minor groove-binding drugs interfere with gene expression by precluding intramolecular triplex formation, as well as by physically preventing regulatory protein binding.
Vigneswaran
N
N
Department of Stomatology, The University of Texas-Houston Dental Branch, 77030, USA.
Thayaparan
J
J
Knops
J
J
Trent
J
J
Potaman
V
V
Miller
D M
DM
Zacharias
W
W
D000818:Animals; D000906:Antibodies / Q000378:metabolism; D001483:Base Sequence; D001665:Binding Sites; D002478:Cells, Cultured; D004214:Distamycins / Q000378:metabolism / Q000494:pharmacology; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D051379:Mice; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009690:Nucleic Acid Conformation; D009692:Nucleic Acid Heteroduplexes / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology*; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology; D008926:Plicamycin / Q000378:metabolism / Q000494:pharmacology*; D011401:Promoter Regions, Genetic; D000090063:Proto-Oncogene Mas; D020598:Proto-Oncogene Proteins c-myb / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D011687:Purines / Q000737:chemistry / Q000378:metabolism; D011743:Pyrimidines / Q000737:chemistry / Q000378:metabolism; D015719:Single-Strand Specific DNA and RNA Endonucleases / Q000378:metabolism
D000906:Antibodies; D004214:Distamycins; C000715470:MAS1 protein, human; D009692:Nucleic Acid Heteroduplexes; D019384:Nucleic Acid Synthesis Inhibitors; D009838:Oligodeoxyribonucleotides; D000090063:Proto-Oncogene Mas; D020598:Proto-Oncogene Proteins c-myb; D011687:Purines; D011743:Pyrimidines; C030000:stallimycin; D015719:Single-Strand Specific DNA and RNA Endonucleases; C030986:pyrimidine; D008926:Plicamycin; C030985:purine